Nuestros blogs explican las afecciones de salud y la investigación clínica de una manera fácil de entender, para que los lectores se sientan más informados.
5 obstáculos a los que te enfrentarás al diversificar los ensayos clínicos
Minority participation in clinical trials is an important topic in public health discussions. This representation touches on issues of equality and the elimination of disparities, which are core values of the field. The FDA Safety and Innovation Act introduced in 2012,...
Un nuevo antibiótico combate eficazmente la resistencia bacteriana
Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come. The researchers, led by Dale Boger, co-chair of TSRI’s...
6 Reasons to Diversify Clinical Trials
Starting from the fact that minorities account for fewer than 10 percent of patients enrolled in clinical trials. Health disparities and underrepresentation in clinical trials could become a serious issue in the upcoming years. FDA Regulations In 2012 Congress included Section...
Anti-diabetic Drugs Research – Designing Better Drugs to Treat Type 2 Diabetes
Research led by the University of Adelaide is paving the way for safer and more effective drugs to treat type 2 diabetes, reducing side effects and the need for insulin injections. Two studies, published in the Journal of Medicinal Chemistry and BBA-General Subjects, have...
Un medicamento para la artritis psoriásica muestra resultados prometedores en un ensayo de fase III
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced a significant reduction in symptoms, including joint tenderness and swelling, when...
Clinical Trials Diversity – More Minorities Needed to Make Research Relevant to All
Minorities, in fact, account for fewer than 10 percent of patients enrolled in clinical trials, according to the National Institutes of Health (NIH) National Institute on Minority Health and Health Disparities. Today, Wilkins brings together academic researchers and community members to...
Investigación clínica en Ecuador | Diversidad en la participación de la comunidad hispana
Why Is Diversity Important? FDA Action Plan In 2012 the Food and Drug Administration Safety and Innovation Act was published. Most of this FDA Action plan is based to encourage researchers to include safety and effectiveness data by demographic subgroups, including...
Cancer-Fighting Antibody Emerges During Sclerosis Research
While studying the underpinnings of multiple sclerosis, investigators at Brigham and Women’s Hospital came across important clues for how to treat a very different disease: cancer. In a paper published in Science Immunology, a group of researchers led by neurologist Howard...
Rare Cancer Survival Rate Increased by Almost a Quarter
Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a Cancer Research UK-funded trial, led by the University of Southampton....
Un medicamento contra el cáncer resulta eficaz para el tratamiento de la insuficiencia cardíaca, según un estudio preclínico
Preclinical Cancer Drug Discoveries Researchers from the Gladstone Institutes have discovered that newly-developed cancer drugs may also provide a treatment option for heart failure patients. Heart failure is the leading cause of mortality, hospitalization and healthcare costs in the U.S. Even...
ADHD Medication Associated with Reduced Risk of Motor Vehicle Crashes
In a study of more than 2.3 million patients in the United States with attention-deficit/hyperactivity disorder (ADHD), rates of motor vehicle crashes (MVCs) were lower when they had received their medication, according to a new article published by JAMA Psychiatry. About 1.25...
La FDA aprueba el primer medicamento nuevo para la ELA en más de 20 años
The Food and Drug Administration has approved the drug Radicava, also known as edaravone, for the treatment for amyotrophic lateral sclerosis (ALS). This is the first time an ALS drug has been cleared for use in the U.S. since the drug...